{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:56:00Z","timestamp":1790117760037,"version":"4.0.1"},"reference-count":92,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.2217\/imt-2020-0336","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T13:33:40Z","timestamp":1625060020000},"page":"1053-1065","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":34,"title":["PD-L1 Expression as a Predictive Biomarker For Immune Checkpoint Inhibitors: Between a Dream And a Nightmare"],"prefix":"10.1080","volume":"13","author":[{"given":"Joseph","family":"Zouein","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Kesrouani","sequence":"additional","affiliation":[{"name":"Department of\u00a0Pathology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampig Raphael","family":"Kourie","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.03.017"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0029"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0191-1"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.12.018"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00209-0"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30406-5"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2019.303644"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"e_1_3_3_11_1","unstructured":"US FDA . FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication (2017). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication"},{"key":"e_1_3_3_12_1","unstructured":"US FDA . FDA approves pembrolizumab for first-line treatment of MSI-H\/dMMR colorectal cancer (2020). www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00729-2"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444"},{"key":"e_1_3_3_16_1","unstructured":"US FDA . FDA approves pembrolizumab for adults and children with TMB-H solid tumors (2020). www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0864-3"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2963"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2017.07.06"},{"key":"e_1_3_3_20_1","unstructured":"Aligent . PD-L1 IHC 22C3 pharmDx (2021). www.agilent.com\/en\/product\/pharmdx\/pd-l1-ihc-22c3-pharmdx"},{"key":"e_1_3_3_21_1","unstructured":"Aligent . PD-L1 IHC 28-8 pharmDx interpretation (2021). www.agilent.com\/cs\/library\/usermanuals\/public\/29120_pd-l1-ihc-28-8-interpretation-manual-melanoma.pdf"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918763493"},{"key":"e_1_3_3_23_1","unstructured":"Roche . VENTANA PD-L1 (SP142) Assay (CE IVD) (2021). https:\/\/diagnostics.roche.com\/global\/en\/products\/tests\/ventana-pd-l1-_sp142-assay2.html"},{"key":"e_1_3_3_24_1","unstructured":"Roche . VENTANA PD-L1 (SP263) Assay (CE IVD) (2021). https:\/\/diagnostics.roche.com\/global\/en\/products\/tests\/ventana-pd-l1-_sp263-assay2.html"},{"key":"e_1_3_3_25_1","unstructured":"US FDA . FDA limits the use of Tecentriq and Keytruda for some urothelial cancer patients (2018). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-limits-use-tecentriq-and-keytruda-some-urothelial-cancer-patients"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.047"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_3_3_29_1","unstructured":"US FDA . FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer (2019). www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2244"},{"key":"e_1_3_3_31_1","unstructured":"US FDA . FDA issues alert about efficacy and potential safety concerns with atezolizumab in combination with paclitaxel for treatment of breast cancer (2020). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-issues-alert-about-efficacy-and-potential-safety-concerns-atezolizumab-combination-paclitaxel"},{"key":"e_1_3_3_32_1","unstructured":"US FDA . FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression (2020). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2284"},{"key":"e_1_3_3_36_1","unstructured":"US FDA . Pembrolizumab (KEYTRUDA) Checkpoint Inhibitor (2019). www.fda.gov\/drugs\/resources-information-approved-drugs\/pembrolizumab-keytruda-checkpoint-inhibitor"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.584"},{"key":"e_1_3_3_39_1","unstructured":"US FDA . FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS \u22651%) (2019). www.fda.gov\/drugs\/fda-expands-pembrolizumab-indication-first-line-treatment-nsclc-tps-1"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2"},{"key":"e_1_3_3_41_1","unstructured":"US FDA . Pembrolizumab (Keytruda): advanced or metastatic urothelial carcinoma (2017). www.fda.gov\/drugs\/resources-information-approved-drugs\/pembrolizumab-keytruda-advanced-or-metastatic-urothelial-carcinoma"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01213"},{"key":"e_1_3_3_43_1","unstructured":"US FDA . FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma (2019). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-first-line-treatment-head-and-neck-squamous-cell-carcinoma"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1030"},{"key":"e_1_3_3_46_1","unstructured":"US FDA . FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancer (2020). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-locally-recurrent-unresectable-or-metastatic-triple"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.1000"},{"key":"e_1_3_3_49_1","unstructured":"US FDA . FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy (2018). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-advanced-cervical-cancer-disease-progression-during-or-after-chemotherapy"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01265"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz422.002"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01888"},{"key":"e_1_3_3_54_1","unstructured":"US FDA . FDA grants accelerated approval to pembrolizumab for advanced gastric cancer (2017). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-advanced-gastric-cancer"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4009"},{"key":"e_1_3_3_57_1","unstructured":"US FDA . FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC (2018). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-after-chemoradiation-unresectable-stage-iii-nsclc"},{"key":"e_1_3_3_58_1","unstructured":"US FDA . Durvalumab (Imfinzi) (2017). www.fda.gov\/drugs\/resources-information-approved-drugs\/durvalumab-imfinzi"},{"key":"e_1_3_3_59_1","unstructured":"ESMO . EMA recommends extension of indications for durvalumab (2020). www.esmo.org\/oncology-news\/ema-recommends-extension-of-indications-for-durvalumab"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697"},{"key":"e_1_3_3_61_1","unstructured":"US FDA . FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression \u22651%) (2020). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-plus-ipilimumab-and-chemotherapy-first-line-treatment-metastatic-nsclc"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9500"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03140-2"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020201"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02520-z"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.20015"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.09.001"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124507"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.06.005"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.10.24"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091269"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0983"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0372-z"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3015"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-020-02976-5"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-019-0366-y"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.2228"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.013"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.247"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584626"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.569219"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.587460"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180870"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02022"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.08.009"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.03.002"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.30197"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.02.016"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201916039"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0392-8"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8839978"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.204.Supp.90.10"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001698"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2020-0336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:52:49Z","timestamp":1715993569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2020-0336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":92,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.2217\/imt-2020-0336"],"URL":"https:\/\/doi.org\/10.2217\/imt-2020-0336","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}